S*BIO Grants License to Tragara for Inhibitor Development
- Posted on 22 January 2009
S*BIO has granted a worldwide exclusive license to Tragara Pharmaceuticals to develop and
commercialize the former’s multi-kinase inhibitor SB1317.
Under the terms of the agreement S*BIO is eligible to receive up to $112.5 million in payments.
This includes an upfront fee, development and sales milestone payments and up to double-digit
royalties.
The company will perform certain preclinical activities for Tragara under a defined
workplan in return for research fees.
The latter is responsible for all IND enabling, development and commercialization activities under the agreement. SB1317 development will be initially focused on the treatment of hematologic malignancies and Tragara will also explore the therapeutic potential of the compound’s activity in solid tumors.
